So those things together, the cargo of the new – the Zinc Fingers plus the capsids that are able to deliver to the specific brain regions, we think will make a really transformative impact into these neurological diseases.
Sandy Macrae : Amy, we are also using ASOs that we have to inject often or inject into the sequel in. Why will ours be once and done?
Amy Pooler: That’s right, because neurons and other brain cells are usually terminally differentiated. It means that we predict that the expression of the Zinc Fingers will be durable. And that’s the lifetime of the patients. This is what we believe will be the case and we look forward to showing that in clinic. But it does mean, we have a one and done approach.
Nishant Poddar: Thank you.
Operator: Please stand by for the next question. The next question comes from Patrick Trucchio with H.C. Wainwright. Your line is open.
Unidentified Analyst: Hi, everyone. Thank you for taking the call. This is Louis for Patrick. Just like to ask about the newer programs that you still have going on for Alzheimer’s we tell and Parkinson’s with Alpha-synuclein. You said, you have, you’ve announced because we have increased penetration with the brain capsids. So you’re going to prioritize these programs now. When we’re going to see more data from them?
Sandy Macrae : Amy, can you talk about where we are with tauopa that’s been interesting data and so recently hasn’t learned.
Amy Pooler: Absolutely. I mean, with our previous partnership, we’re able to progress that program quite a long ways. We have our clinical lead, Zinc Finger which was really been able to show some potent and specific repression of tau in the brains of our preclinical models. And we look forward to pairing that in future potentially with a Blood-Brain Barrier capsid that would enable delivery across the nervous system.
Sandy Macrae: And the results of those have shown in tau gives us reasons to believe in this as a target.
Amy Pooler: Yeah, absolutely. It’s really been some fantastic data that’s coming out in the field now showing that specific reduction of tau is able to remove some of the nervous ability tangles just some of the pathology that’s related to tau. So we think that, that gives even more evidence that a tau targeted approach could be critical for treating something like Alzheimer’s disease, and also other tau is.
Unidentified Analyst: Thank you.
Operator: [Operator Instructions] Please stand by for the next question. The next question comes from Yanan Zhu with Wells Fargo Securities. Your line is open.
Unidentified Analyst: Hi, thanks for taking our question. This is [Indiscernible] for Yanan. So, our first question on Tx200. I wonder even though it’s only like two cohorts, but I wonder if you have seen any dose response and any immunosuppressant tapering? And what are the potential partners might be looking for? Thanks you.
Sandy Macrae: So there’s two parts to that question. We’ve only dosed one patient in cohort two and they’re only recently dosed. So it would not be possible to know if there’s any benefit nor have this started any process of tapering. As I said, there is going to be so much more rich data set to show you the whole package next year. What our partners looking for, there are many CAR-Treg companies. I think I count over 10 of them and they’ve all been funded and founded on preclinical promise. And Sangamo is like the field here and we’re the only patient – the only one that is publicly said we’re in the clinic. And the fact that we’ve shown that we can dose four patients with CAR-Tregs and it is safe. I think is I really important thing for the whole field.
